(Q80184830)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Current treatment options in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Adrienne Boissy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Robert J Fox

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

Current treatment options in neurology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

176-186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf02938407

29 December 2019

exact match

0 references

cites work

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

12 December 2020

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

1 reference

12 December 2020

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis

1 reference

12 December 2020

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study

1 reference

12 December 2020

Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women

1 reference

12 December 2020

Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

T-cell vaccination in multiple sclerosis: update on clinical application and mode of action

1 reference

12 December 2020

Treatment of Pediatric Multiple Sclerosis

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

1 reference

12 December 2020

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

12 December 2020

Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis

1 reference

12 December 2020

Cigarette smoking and incidence of multiple sclerosis

1 reference

12 December 2020

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

12 December 2020

Does interferon beta help in secondary progressive MS?

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

1 reference

12 December 2020

1 reference

12 December 2020

Vitamin D intake and incidence of multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

Cigarette smoking and the progression of multiple sclerosis.

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02938407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17445495%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference